Small bowel enteropathies that are associated with an autoimmune process are often resistant to treatment. Two children with autoimmune enteropathy were treated with cyclosporin A for eight months. Both improved, as assessed by growth, small intestinal mucosal morphology, and carbohydrate absorption. Cyclosporin A is useful in the treatment of autoimmune enteropathy. This report also suggests that T cell activation (which is suppressed by cyclosporin A) is important in the pathogenesis ofthis condition.
A proportion of children presenting with chronic diarrhoea and small intestinal enteropathy suffer from an autoimmune process. In one series, enterocyte autoantibodies were found in over 50% of infants with intractable diarrhoea.' The criteria for the diagnosis of an autoimmune enteropathy have been defined as follows:2 (a) Presentation with chronic diarrhoea and a severe small intestinal enteropathy; (b) No response to exclusion diets; (c) Evidence of predisposition to autoimmune disease (presence of circulating gut autoantibodies or associated autoimmune disease, or both); (d) Immunocompetence. The treatment of children with this condition remains unsatisfactory and a number of children have died.
Activation of T lymphocytes is now believed to be the mechanism by which many organ specific autoimmune diseases are mediated. 3 Cyclosporin A has been widely used as an immuosuppressive agent in autoimmune diseases. 4 Activation of T cells produces a severe enteropathy in an in vitro fetal intestinal organ culture.5 These changes could be prevented by cyclosporin A treatment and this provided a rational basis for its use in two children with an autoimmune enteropathy.
Methods

PATIENTS
Two children with an autoimmune enteropathy were chosen for treatment with cyclosporin A. Their early clinical history has been described previously' 26 and they satisfy the criteria for the diagnosis of autoimmune enteropathy listed above.
Immediately before the start of cyclosporin A treatment, proximal small intestinal biopsy specimens from both patient 1 (a boy aged 9.5 years) and patient 2 (a girl aged 12-3 years) (Fig 1) but electron microscopy showed that the ultrastructural appearance of the epithelium had reverted to normal (Fig 2) . Patient 2 showed both light and electron microscopic improvement. (Table III) . There was a relatively greater reduction in those cells that expressed the yb T cell receptor, though because of the low numbers of cells expressing the T cell receptor this may not be significant. In the lamina propria, the number ofnucleated cells expressing CD3 fell only in patient 2; however, there was a fall in the percentage of cells expressing CD25 in both patients. CARBOHYDRATE ABSORPTION Figure 3 shows the effects of cyclosporin A on the two hour blood glucose profile of patient 1. Glucose concentrations were greater after a 50 g oral load during cyclosporin A treatment. This figure also shows that there was no difference in the insulin response to the load (probably because this response was maximal on both occasions). This result can be explained by increased carbohydrate transfer by the intestine.
The insulin dosage needed to maintain glucose homeostasis in patient 2 (as assessed by regular home blood sugar monitoring) increased from 25 U daily (1 1 U/kg/day) to 52 U (1.9 U/kg/day) after 8 months' cyclosporin A therapy. During the same period the intake of carbohydrate was reduced from 240-290 g per day to 200-230 g per day. This indicates increased carbohydrate absorption by the intestine.
ADVERSE EFFECTS
There was no deterioration of glomerular function as shown by creatinine concentrations in patient 2. The glomerular filtration rate of patient 1 on entry to the study was 28 ml/min/ 1-73 m2, and after eight months' cyclosporin A treatment it was 26 ml/min/1 73m2. This change is not significant, as it is within the accuracy of the technique.
Although both children were noted to have developed increased hair on their limbs and over the back, this was not sufficient to cause concern to them or their parents.
Discussion
This report clearly shows the benefit of cyclosporin A treatment in these two children with autoimmune enteropathy who had been unwell for many years. Not only was the treatment beneficial, as shown by its effect on intestinal structure and function, but it also led to an acceleration of linear growth that was not related to puberty.
Cyclosporin A suspends certain nuclear events associated with T cell activation.'0 Cytotoxic lymphocytes are inhibited from acquiring responsiveness to interleukin 2." Interleukin 2 production is inhibited both in the primary response to antigen'2 and in response to antigen restimulation.'3 Also interleukin 1 production of antigen presenting cells is curtailed.'4 In our patients, interleukin 2 receptor expression, a marker of T cell activation, was reduced within the lamina propria after treatment with cyclosporin A. T cell activation can cause an entero- The importance of autoantibody in the pathogenesis of the mucosal damage has been questioned. Antibody concentrations do not necessarily correlate to the severity of disease. Indeed, circulating autoantibodies have not been detected in some patients at the time of presentation, but occurred at a later date. Interestingly, an autoimmune enteropathy has been described in a patient with common variable immunodeficiency in whom production of IgG and IgA class antibodies by plasma cells was defective. '7 These inconsistencies can now be resolved because T cell activation, which is the primary event in autoimmune disease, does not necessarily cause the organ damage by way of B cell activation and antibody production, which may be a secondary phenomenon. An example of an autoimmune disease where T cell induced damage is caused by a cellular mechanism is experimental autoimmune uveal retinitis seen in the rat.'8 In this condition, autoantibodies are produced against a retinal antigen, yet the disease is mediated by T cells. T cell activation can be prevented by using cyclosporin A, with consequent prevention of ocular inflammation, yet circulating autoantibodies are still produced.
We adopted a cautious approach to the amount of cyclosporin A prescribed. Interestingly, the circulating concentrations that were effective were lower than those commonly used in prevention of organ transplantation rejection. Adverse effects of the drug are therefore less likely. Indeed the only side effect noted was mild hirsutism. It is, however, impossible to predict the long term effect of this treatment;
In conclusion, cyclosporin A has been shown to be useful in the treatment of autoimmune enteropathy. Its efficacy suggests that activation of T cells are central to the pathogenesis of this condition.
